

Imbruvica - (70MG/1ML ; Suspension)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Ibrutinib | Innovator | Pharmacyclics |
| Dosage | 70MG/1ML ; Suspension | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. • Waldenström's macroglobulinemia (WM). • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.